blink-182‘s Mark Hoppus has revealed he has been battling cancer, sharing the news of his diagnosis in a post to his social media accounts.
“For the past three months I’ve been undergoing chemotherapy for cancer. I have cancer,” Hoppus wrote. “It sucks and I’m scared, and at the same time I’m blessed with incredible doctors and family and friends to get me through this.”
He continued: “I still have months of treatment ahead of me but I’m trying to remain hopeful and positive. Can’t wait to be cancer free and see you all at a concert in the near future. Love to you all.” See Hoppus’ post below.
https://twitter.com/markhoppus/status/1407822798190383109
Prior to confirming the news, Hoppus had shared an Instagram story alluding to his diagnosis. In the since-deleted story, the pop-punk icon can be seen in a doctor’s office surrounded by medical equipment, with the caption, “Yes hello. One cancer treatment, please.”
Hoppus received an outpouring of support following his news, including from All Time Low‘s Alex Gaskarth – who Hoppus performs with in the duo Simple Creatures – along with A Day to Remember‘s Alex Shelnutt and The Office actor B.J. Novak.
Tom DeLonge, Hoppus’ former blink-182 bandmate, also offered his support. “I too, have been aware of [Hoppus’] cancer diagnosis for awhile now,” DeLonge wrote on Twitter.
“And to add to his own words that he used today, I would also like to say that he is strong, and a super-human who is pushing through this difficult obstacle with a wide-open heart.”
I too, have been aware of @markhoppus’s cancer diagnosis for awhile now. And to add to his own words that he used today, I would also like to say that he is strong, and a super-human who is pushing through this difficult obstacle with a wide-open heart. ??#WeHaveHisBack
— Tom DeLonge (@tomdelonge) June 24, 2021
Hoppus’ most recent album with blink-182 was 2019’s Nine. He released two EPs with Simple Creatures – Strange Love and Everything Opposite – the same year. Last year, blink also shared the standalone single ‘Quarantine’.